PepGen Inc./$PEPG
1D1W1MYTD1Y5YMAX
Capital at risk
About PepGen Inc.
PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics to transform the treatment of severe neuromuscular and neurologic diseases. The company has developed its Enhanced Delivery Oligonucleotide platform to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake, and nuclear delivery, and in preclinical studies, it is observed that their ability to transport oligonucleotides into a broad range of target tissues, including smooth, skeletal, and cardiac muscle, and the central nervous system. Its pipeline products are: PGN-EDO51, PGN-EDODM1, and others.
- Ticker
- $PEPG
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 57
- Headquarters
- Boston, United States
- Website
- www.pepgen.com
PepGen Inc. Metrics
BasicAdvanced
$206M
-
-$1.19
1.89
-
Price and volume
Market cap
$206M
Beta
1.89
52-week high
$7.80
52-week low
$1.31
Average daily volume
975K
Financial strength
Current ratio
13.362
Quick ratio
13.019
Long term debt to equity
0.108
Total debt to equity
0.135
Profitability
EBITDA (TTM)
-74.994
Effective tax rate (TTM)
-0.11%
Management effectiveness
Return on assets (TTM)
-39.12%
Return on equity (TTM)
-75.45%
Valuation
Price to book
1.72
Price to tangible book (TTM)
1.72
Price to free cash flow (TTM)
-2.584
Free cash flow yield (TTM)
-38.70%
Free cash flow per share (TTM)
-1.149
Growth
Earnings per share change (TTM)
-59.89%
3-year earnings per share growth (CAGR)
-25.87%
Upcoming events
No upcoming events
PepGen Inc. News
AllArticlesVideos
Funds containing PepGen Inc.
AllUSDGBP
Fund name | Fund size | $PEPG weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.01% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 0.01% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.